BioRestorative Therapies Inc
BioRestorative Therapies, Inc. develops therapeutic products and medical therapies using cell and tissue protocols primarily involving adult stem cells. It develops programs relate to the treatment of disc/spine disease and metabolic disorders. The company's products pipeline comprises BRTX-100, a lead cell therapy candidate formulated from autologous cultured mesenchymal stem cells collected fro… Read more
BioRestorative Therapies Inc (BRTX) - Total Assets
Latest total assets as of September 2025: $5.64 Million USD
Based on the latest financial reports, BioRestorative Therapies Inc (BRTX) holds total assets worth $5.64 Million USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
BioRestorative Therapies Inc - Total Assets Trend (2009–2024)
This chart illustrates how BioRestorative Therapies Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
BioRestorative Therapies Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
BioRestorative Therapies Inc's total assets of $5.64 Million consist of 90.8% current assets and 9.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 4.5% |
| Accounts Receivable | $188.40K | 1.5% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $623.95K | 5.1% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2009–2024)
This chart illustrates how BioRestorative Therapies Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: BioRestorative Therapies Inc's current assets represent 90.8% of total assets in 2024, an increase from 0.0% in 2009.
- Cash Position: Cash and equivalents constituted 4.5% of total assets in 2024, up from 0.0% in 2009.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 5.0% of total assets, a decrease from 98.0% in 2009.
- Asset Diversification: The largest asset category is intangible assets at 5.1% of total assets.
BioRestorative Therapies Inc Competitors by Total Assets
Key competitors of BioRestorative Therapies Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
BioRestorative Therapies Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - BioRestorative Therapies Inc generates 0.03x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - BioRestorative Therapies Inc is currently not profitable relative to its asset base.
BioRestorative Therapies Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.37 | 2.95 | 0.01 |
| Quick Ratio | 1.37 | 2.95 | 0.01 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $1.26 Million | $ 8.93 Million | $ -13.65 Million |
BioRestorative Therapies Inc - Advanced Valuation Insights
This section examines the relationship between BioRestorative Therapies Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.15 |
| Latest Market Cap to Assets Ratio | 0.12 |
| Asset Growth Rate (YoY) | -2.6% |
| Total Assets | $12.28 Million |
| Market Capitalization | $1.51 Million USD |
Valuation Analysis
Below Book Valuation: The market values BioRestorative Therapies Inc's assets below their book value (0.12 x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: BioRestorative Therapies Inc's assets decreased by 2.6% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for BioRestorative Therapies Inc (2009–2024)
The table below shows the annual total assets of BioRestorative Therapies Inc from 2009 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $12.28 Million | -2.63% |
| 2023-12-31 | $12.61 Million | -23.26% |
| 2022-12-31 | $16.43 Million | -26.81% |
| 2021-12-31 | $22.45 Million | +416.52% |
| 2020-12-31 | $4.35 Million | +196.46% |
| 2019-12-31 | $1.47 Million | +22.97% |
| 2018-12-31 | $1.19 Million | -32.20% |
| 2017-12-31 | $1.76 Million | +11.30% |
| 2016-12-31 | $1.58 Million | -21.67% |
| 2015-12-31 | $2.02 Million | +19.22% |
| 2014-12-31 | $1.69 Million | +22.34% |
| 2013-12-31 | $1.38 Million | +9.06% |
| 2012-12-31 | $1.27 Million | +473.85% |
| 2011-12-31 | $220.97K | -52.83% |
| 2010-12-31 | $468.51K | -93.98% |
| 2009-12-31 | $7.79 Million | -- |